Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited said its controlling shareholder, Tianjin Pharmaceutical Holdings (TPH), lifted its interest in the company through a market purchase on the Singapore Exchange on Feb, 04 2026.

TPH’s wholly owned unit, JinYao Global Pte. Ltd., bought 82,200 S-shares at an average price of about US$2.96 each, spending roughly 0.33 million Singapore dollars. The purchase increased TPH’s holding to 331.20 million shares, or 43.008% of the drug maker’s enlarged share capital, from 42.997% previously.

JinYao Global plans to acquire additional S-shares of up to 1% of the company’s issued capital within six months, with any purchase price capped at US$4.00 a share. Total spending under the plan, including the recent transaction, is expected to be between about 2.7 million and 5.5 million Singapore dollars.

The buyer will use internal funds for the purchases and has pledged not to sell any existing holdings during the programme. The company said the transactions will not affect its public float, listing status or control structure, but cautioned that market conditions could affect the pace or outcome of the buy plan.

Shareholders and potential investors were advised to exercise caution when dealing in the shares.